A novel tumor mutational burden estimation model as a predictive and prognostic biomarker in NSCLC patients

BACKGROUND: Tumor mutational burden (TMB) has both prognostic value in resected non-small cell lung cancer (NSCLC) patients and predictive value for immunotherapy response. However, TMB evaluation by whole-exome sequencing (WES) is expensive and time-consuming, hampering its application in clinical...

Descripción completa

Detalles Bibliográficos
Autores principales: Tian, Yanhua, Xu, Jiachen, Chu, Qian, Duan, Jianchun, Zhang, Jianjun, Bai, Hua, Yang, Zhenlin, Fang, Wenfeng, Cai, Liangliang, Wan, Rui, Fei, Kailun, He, Jie, Gao, Shugeng, Zhang, Li, Wang, Zhijie, Wang, Jie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7448445/
https://www.ncbi.nlm.nih.gov/pubmed/32843031
http://dx.doi.org/10.1186/s12916-020-01694-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7448445/
https://www.ncbi.nlm.nih.gov/pubmed/32843031
http://dx.doi.org/10.1186/s12916-020-01694-8

Ejemplares similares